"Germany Pharmaceuticals & Healthcare Report Q2 2012" Now Available at Fast Market Research
BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic competition as a result of the patent cliff, we expect Germany to remain attractive to innovative drugmakers. In 2011, Germany's drug market was the fourth largest globally after the US, Japan and China. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will...
View full press release